Biomedical research at Oslo University Hospital

Publications (original articles or review articles) published in 2018 from OUS - National Advisory Unit on Late Effects after Cancer Treatment

22 publications found

Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, Ferrer F, Boladeras A, Zamora V, Fosså S, Storås AH, Sanda M, Serra-Sutton V, Ferrer M (2018)
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis
Cancer Treat Rev, 66, 23-44
DOI 10.1016/j.ctrv.2018.03.005, PubMed 29673922

Buffart LM, Sweegers MG, May AM, Chinapaw MJ, van Vulpen JK, Newton RU, Galvão DA, Aaronson NK, Stuiver MM, Jacobsen PB, Verdonck-de Leeuw IM, Steindorf K, Irwin ML, Hayes S, Griffith KA, Lucia A, Herrero-Roman F, Mesters I, van Weert E, Knoop H, Goedendorp MM, Mutrie N, Daley AJ, McConnachie A, Bohus M et al. (2018)
Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis
J Natl Cancer Inst, 110 (11), 1190-1200
DOI 10.1093/jnci/djy161, PubMed 30299508

Bøhn SH, Fosså SD, Wisløff T, Thorsen L (2018)
Physical activity and associations with treatment-induced adverse effects among prostate cancer patients
Support Care Cancer, 27 (3), 1001-1011
DOI 10.1007/s00520-018-4389-5, PubMed 30094728

Eichenauer DA, André M, Johnson P, Fossa A, Casasnovas O, Engert A (2018)
Controversies in the Treatment of Classical Hodgkin Lymphoma
Hemasphere, 2 (5), e149
DOI 10.1097/HS9.0000000000000149, PubMed 30887012

Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Zaid MA, Lipshultz SE, Einhorn LH, Oeffinger KC, Travis LB, Fossa SD, Platinum Study Group (2018)
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score
Clin Genitourin Cancer, 16 (4), e761-e769
DOI 10.1016/j.clgc.2018.01.011, PubMed 29534941

Fossa SD, Fung C, Dahl AA (2018)
Late adverse outcomes after treatment of testicular cancer
Onkologe, 24 2, S104-S109

Fung C, Dinh P, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB (2018)
Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors
Adv Urol, 2018, 8671832
DOI 10.1155/2018/8671832, PubMed 29670654

Georgi TW, Kluge R, Kurch L, Chavdarova L, Hasenclever D, Stoevesandt D, Pelz T, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Fosså A, Balwierz W, Attarbaschi A, Ammann RA, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Baumann J, Körholz D et al. (2018)
¹⁸F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?
J Nucl Med, 59 (10), 1524-1530
DOI 10.2967/jnumed.117.205633, PubMed 29653979

Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD (2018)
Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study
Acta Oncol, 57 (8), 1075-1083
DOI 10.1080/0284186X.2018.1433323, PubMed 29384420

Hjelle LV, Gundersen POM, Hellesnes R, Sprauten M, Brydøy M, Tandstad T, Wilsgaard T, Fosså SD, Oldenburg J, Bremnes RM, Haugnes HS (2018)
Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors
Acta Oncol, 57 (10), 1392-1400
DOI 10.1080/0284186X.2018.1473641, PubMed 29775128

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A et al. (2018)
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Ann Oncol, 29 (8), 1658-1686
DOI 10.1093/annonc/mdy217, PubMed 30113631

Kiserud CE, Dahl AA, Fosså SD (2018)
Cancer Survivorship in Adults
Recent Results Cancer Res, 210, 123-143
DOI 10.1007/978-3-319-64310-6_8, PubMed 28924683

Ryalen PC, Stensrud MJ, Fosså S, Røysland K (2018)
Causal inference in continuous time: an example on prostate cancer therapy
Biostatistics (in press)
DOI 10.1093/biostatistics/kxy036, PubMed 30124773

Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD (2018)
Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
Acta Obstet Gynecol Scand, 98 (2), 240-249
DOI 10.1111/aogs.13477, PubMed 30289161

Sweegers MG, Altenburg TM, Brug J, May AM, van Vulpen JK, Aaronson NK, Arbane G, Bohus M, Courneya KS, Daley AJ, Galvao DA, Garrod R, Griffith KA, Van Harten WH, Hayes SC, Herrero-Román F, Kersten MJ, Lucia A, McConnachie A, van Mechelen W, Mutrie N, Newton RU, Nollet F, Potthoff K, Schmidt ME et al. (2018)
Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data
Br J Sports Med, 53 (13), 812
DOI 10.1136/bjsports-2018-099191, PubMed 30181323

van den Berg M, van Dijk M, Byrne J, Campbell H, Berger C, Borgmann-Staudt A, Calaminus G, Dirksen U, Winther JF, Fossa SD, Grabow D, Grandage VL, van den Heuvel-Eibrink MM, Kaiser M, Kepak T, Kremer LC, Kruseova J, Kuehni CE, Lambalk CB, van Leeuwen FE, Leiper A, Modan-Moses D, Morsellino V, Spix C, Kaatsch P et al. (2018)
Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE)
JMIR Res Protoc, 7 (9), e10824
DOI 10.2196/10824, PubMed 30215599

van der Kooi ALF, Clemens E, Broer L, Zolk O, Byrne J, Campbell H, van den Berg M, Berger C, Calaminus G, Dirksen U, Winther JF, Fosså SD, Grabow D, Haupt R, Kaiser M, Kepak T, Kremer L, Kruseova J, Modan-Moses D, Ranft A, Spix C, Kaatsch P, Laven JSE, van Dulmen-den Broeder E, Uitterlinden AG et al. (2018)
Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol
BMC Cancer, 18 (1), 930
DOI 10.1186/s12885-018-4834-3, PubMed 30257669

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS et al. (2018)
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Blood, 132 (20), 2115-2124
DOI 10.1182/blood-2018-07-862334, PubMed 30181172

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241

Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC, Sesso HD, Einhorn LH, Fossa SD, Travis LB, Platinum Study Group (2018)
Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors
J Natl Compr Canc Netw, 16 (3), 257-265
DOI 10.6004/jnccn.2017.7046, PubMed 29523664

Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V (2018)
Is time from diagnosis to radical prostatectomy associated with oncological outcomes?
World J Urol, 37 (8), 1571-1580
DOI 10.1007/s00345-018-2570-6, PubMed 30483947

Åsli LM, Myklebust TÅ, Kvaløy SO, Jetne V, Møller B, Levernes SG, Johannesen TB (2018)
Factors influencing access to palliative radiotherapy: a Norwegian population-based study
Acta Oncol, 57 (9), 1250-1258
DOI 10.1080/0284186X.2018.1468087, PubMed 29706109